Allelix Clones Receptor For Intestinal Growth Factor GLP-2

Toronto, Canada - February 15, 1999 - Scientists from Allelix Biopharmaceuticals Inc. (TSE/ME: AXB) will report the cloning of the receptor for Glucagon-like Peptide 2 (GLP-2), which plays a unique role in intestinal growth and nutrient absorption, in the February 16 issue of the Proceedings of the National Academy of Sciences. The findings offer valuable information about the specificity and action of GLP-2, for which Allelix has developed a proprietary analog, ALX-0600, as a potential therapy for several gastrointestinal disorders including short bowel syndrome. Because the GLP-2 receptor was found almost exclusively in the small intestine, ALX-0600 is expected to act in a highly specific manner at the target site.

Normally, GLP-2, a peptide hormone, acts in the body as a potent stimulator of cell growth in the lining of the small bowel. This growth dramatically increases the surface area of the intestine, where nutrients are extracted from food and then circulated into the body. Diseases such as short bowel syndrome, in which the decreased surface area results in reduced nutrient absorption, can lead to chronic hospitalizations and even death. No effective treatments are currently available for patients with the most severe form of these diseases.

"The cloning of this naturally occurring receptor is a critical step in determining exactly where and how GLP-2 functions in the body," said first author Donald G. Munroe, Ph.D., senior research scientist at Allelix. "With the cloned human receptor in hand, we are now able to better understand the mechanisms that connect GLP-2 with intestinal growth and nutrient absorption at the cellular and molecular levels."

Allelix has completed work in phase I clinical studies of ALX-0600 for short bowel syndrome, a condition estimated to affect 40,000 to 50,000 sufferers worldwide. Phase II studies are planned for 1999. Allelix is also considering investigational trials for additional clinical indications such

Contact: Ernie Knewitz
212-696-4455 x204
Noonan/Russo Communications

Page: 1 2 3

Related biology news :

1. Allelix drug increases bone density and content in women with osteoporosis
2. Millennium Clones Diet-Induced Obesity Gene
3. International Research Team Clones New Skin Cancer Gene
4. Receptor found that guides nerve cells to their final connecting sites
5. Receptor could be target for cancer therapy
6. Receptor-dependent protein activation without a receptor
7. Researchers Engineer A Way To Improve T-Cell Receptors
8. Studies At Cedars-Sinai Confirm Identity Of An Elusive Receptor In Human Cells -- A Breakthrough In Understanding, Fighting Septic Shock
9. Scientists Discover Function For Type III TGF-Beta Receptor
10. Antiviral From Advanced Viral Research Corp. Inhibits CCR5 Cell Receptor For HIV
11. Scientists Discover Key Cog In Receptor That Governs Ripening

Post Your Comments:

(Date:10/3/2019)... FORT WORTH, Texas (PRWEB) , ... October 01, ... ... to support the aseptic pouring and dispensing of chemicals, reagents, and medias and ... “The second generation CHEM+POUR Bag is the culmination of years of experience and ...
(Date:9/30/2019)... ... ... As human induced pluripotent stem cells (hiPSCs) move closer to becoming a possible ... human heart, there is an increasing need for stable stem cell lines that allow ... easily recorded. A study released today in STEM CELLS details the development of one ...
(Date:9/25/2019)... ... 25, 2019 , ... LeadingBiotech , an exclusive event ... its inaugural South CEO conference to be held on October 8, ... Tulane University, this invitation-only meeting convenes biopharma executives to discuss pressing issues facing ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... ... 01, 2019 , ... Today Cereset®, the only proven non-invasive ... of its randomized research trial for individuals with persisting symptoms following mild-Traumatic Brain ... a non-invasive technology which compares tones delivered to a subject’s brain guided by ...
(Date:10/3/2019)... ... October 02, 2019 , ... Murrieta Genomics , the launch pad ... capital companies in Silicon Valley at a special Life Science showcase event ... held at the JJ Lake Business Center located at 340 E. Middlefield Road in ...
(Date:10/3/2019)... ... October 03, 2019 , ... Yesterday, at the 2019 meeting of ... and director, James L. Sherley, M.D., Ph.D., discussed important design factors that currently limit ... including both developers and suppliers of clinical trials, in his talk Dr. ...
(Date:9/24/2019)... ... , ... Drug resistance has been declared as one of the biggest threats ... of the most serious concerns. Hong Kong cannot be spared from the worsening scourge ... a seven-fold of the figure in 2007 – the year the disease became notifiable ...
Breaking Biology Technology:
Cached News: